Business Context and Reporting Period
Krystal Biotech, Inc. filed this Form 8-K on October 23, 2018, to report the closing of a previously announced underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise event rather than operational financial results. The specific metrics are:
- Shares Sold: 3,000,000 shares in the primary offering plus 450,000 shares from the full exercise of the underwriters' option.
- Offering Price: $20.00 per share.
- Total Shares Issued: 3,450,000 shares.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The material change reported is the increase in the company's equity capital and share count resulting from the closing of the public offering and the full exercise of the over-allotment option on October 19, 2018.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the equity offering. The event is categorized under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the total gross proceeds from the sale of 3,450,000 shares at $20.00 per share.
- Confirm the net proceeds after deducting underwriting discounts and commissions.
- Review the attached Press Release (Exhibit 99.1) for the intended use of proceeds.
- Check subsequent filings for the updated fully diluted share count and impact on earnings per share.